In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on InflaRx (IFRX – Research Report). The company’s shares closed today at $4.00.
Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, InflaRx, and ALX Oncology Holdings. According to TipRanks, Slutsky has an average return of 1.8% and a 39.43% success rate on recommended stocks.
InflaRx has an analyst consensus of Moderate Buy, with a price target consensus of $9.00, a 125.00% upside from current levels. In a report released on August 30, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $7.25 and a one-year low of $1.57. Currently, InflaRx has an average volume of 202.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Read More on IFRX:
- InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
- InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
- InflaRx MAA for vilobelimab under review by EMA
- InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
- InflaRx expects cash to fund operations at least into 2026
